Abstract 3147: Pinostilbene exhibits anticancer activity in advanced prostate cancer

Abstract Prostate cancer is the foremost incident cancer and the second major cause of cancer-associated mortality among men in the U.S. Although current therapies, involving androgen receptor (AR) pathway inhibitors have improved survival rates, advanced prostate cancer remains a lethal disease. Therefore, new therapeutic approaches should continue to be investigated. Previous studies from our group as well as others have widely demonstrated the anticancer activity of resveratrol and its analogs. However, pinostilbene, a monomethylated resveratrol analog, is less well studied and reports on its anticancer activity in prostate cancer is limited. In this study, we investigated the anticancer activity of pinostilbene in prostate cancer. We found that pinostilbene inhibited the viability, proliferation, and metastatic potential of all prostate cancer cell lines tested. Of note, pinostilbene exhibited significantly higher potency as an anticancer agent in more invasive compared to less invasive prostate cancer cell lines. Overall, our results demonstrate that pinostilbene shows tremendous potential as an anticancer agent for improved management of prostate cancer. Citation Format: Ekniel Francois, Prashanth Reddy Parupathi, Sirisha Devarakonda, Avinash Kumar. Pinostilbene exhibits anticancer activity in advanced prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3147.